Literature DB >> 12551845

Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.

Andrea Savarino1, Thea Bensi, Annalisa Chiocchetti, Flavia Bottarel, Riccardo Mesturini, Enza Ferrero, Liliana Calosso, Silvia Deaglio, Erika Ortolan, Stefano Buttò, Aurelio Cafaro, Toshiaki Katada, Barbara Ensoli, Fabio Malavasi, Umberto Dianzani.   

Abstract

CD38 is a progression marker in HIV-1 infection, it displays lateral association with CD4, and down-modulates gp120/CD4 binding. The aim of this study was to elucidate the mechanism behind the interplay between CD4, CD38, and HIV-1. We used mouse cell transfectants expressing human CD4 and either CD38 or other CD4-associated molecules to show that CD38 specifically inhibits gp120/CD4 binding. Human cell transfectants expressing truncated forms of CD38 and bioinformatic analysis were used to map the anti-HIV activity and show that it is concentrated in the membrane-proximal region. This region displayed significant sequence-similarity with the V3 loop of the HIV-1 gp120 glycoprotein. In line with this similarity, synthetic soluble peptides derived from this region reproduced the anti-HIV effects of full-length CD38 and inhibited HIV-1 and HIV-2 primary isolates from different subtypes and with different coreceptor use. A multiple-branched peptide construct presenting part of the sequence of the V3-like region potently and selectively inhibited HIV-1 replication in the nanomolar range. Conversely, a deletion in the V3-like region abrogated the anti-HIV-1 activity of CD38 and its lateral association with CD4. These findings may provide new insights into the early events of HIV-1 fusion and strategies to intervene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551845     DOI: 10.1096/fj.02-0512fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  Quantitative proteomic analysis of exosomes from HIV-1-infected lymphocytic cells.

Authors:  Ming Li; Jason M Aliotta; John M Asara; Lynne Tucker; Peter Quesenberry; Michelle Lally; Bharat Ramratnam
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

Review 2.  Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization.

Authors:  Hon Cheung Lee
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 3.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

4.  'Click cyclic ADP-ribose': a neutral second messenger mimic.

Authors:  Joanna M Swarbrick; Richard Graeff; Clive Garnham; Mark P Thomas; Antony Galione; Barry V L Potter
Journal:  Chem Commun (Camb)       Date:  2014-01-23       Impact factor: 6.222

5.  Second messenger analogues highlight unexpected substrate sensitivity of CD38: total synthesis of the hybrid "L-cyclic inosine 5'-diphosphate ribose".

Authors:  Joanna M Watt; Richard Graeff; Mark P Thomas; Barry V L Potter
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

6.  Vitamin D treatment of peripheral blood mononuclear cells modulated immune activation and reduced susceptibility to HIV-1 infection of CD4+ T lymphocytes.

Authors:  Sandra M Gonzalez; Wbeimar Aguilar-Jimenez; Edison Trujillo-Gil; Wildeman Zapata; Ruey-Chyi Su; T Blake Ball; Maria T Rugeles
Journal:  PLoS One       Date:  2019-09-24       Impact factor: 3.240

7.  Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque.

Authors:  Enza Ferrero; Monia Orciani; Paola Vacca; Erika Ortolan; Sergio Crovella; Fausto Titti; Franca Saccucci; Fabio Malavasi
Journal:  BMC Immunol       Date:  2004-09-21       Impact factor: 3.615

8.  Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.

Authors:  Joanna M Swarbrick; Richard Graeff; Hongmin Zhang; Mark P Thomas; Quan Hao; Barry V L Potter
Journal:  J Med Chem       Date:  2014-10-01       Impact factor: 7.446

9.  Immuno-targeting the multifunctional CD38 using nanobody.

Authors:  Ting Li; Shali Qi; Mandy Unger; Yun Nan Hou; Qi Wen Deng; Jun Liu; Connie M C Lam; Xian Wang Wang; Du Xin; Peng Zhang; Friedrich Koch-Nolte; Quan Hao; Hongmin Zhang; Hon Cheung Lee; Yong Juan Zhao
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

Review 10.  Roles of CD38 in the Immune Response to Infection.

Authors:  Estibaliz Glaría; Annabel F Valledor
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.